{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T04:03:22Z","timestamp":1751601802616,"version":"3.41.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,2]]},"DOI":"10.7759\/cureus.87203","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T06:24:08Z","timestamp":1751523848000},"source":"Crossref","is-referenced-by-count":0,"title":["A Challenging Case of Wild-Type Transthyretin Amyloidosis (ATTR) Amyloidosis Treated With Cardiac Resynchronization Therapy"],"prefix":"10.7759","author":[{"given":"Hiroki","family":"Bansho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Tomioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Geshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini G","year":"2003","unstructured":"Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003, 349:583-96. 10.1056\/NEJMra023144","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient\u00a0With cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson MM","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, et al.. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient\u00a0With cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023, 81:1076-126. 10.1016\/j.jacc.2022.11.022","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-20-0910","article-title":"JCS\/JHFS 2018 guideline on the diagnosis and treatment of cardiomyopathies","volume":"85","author":"Kitaoka H","year":"2021","unstructured":"Kitaoka H, Tsutsui H, Kubo T, et al.. JCS\/JHFS 2018 guideline on the diagnosis and treatment of cardiomyopathies. Circ J. 2021, 85:1590-689. 10.1253\/circj.CJ-20-0910","journal-title":"Circ J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2017.1409706","article-title":"First nationwide survey on systemic wild-type ATTR amyloidosis in Japan","volume":"25","author":"Sekijima Y","year":"2018","unstructured":"Sekijima Y, Yazaki M, Ueda M, et al.. First nationwide survey on systemic wild-type ATTR amyloidosis in Japan. Amyloid. 2018, 25:8-10. 10.1080\/13506129.2017.1409706","journal-title":"Amyloid"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer MS","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al.. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018, 379:1007-16. 10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvae044","article-title":"Pharmacological management of transthyretin amyloid cardiomyopathy: a scoping review","volume":"10","author":"Rehman S","year":"2024","unstructured":"Rehman S, Masthan SS, Ibrahim R, et al.. Pharmacological management of transthyretin amyloid cardiomyopathy: a scoping review. Eur Heart J Cardiovasc Pharmacother. 2024, 10:547-56. 10.1093\/ehjcvp\/pvae044","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-019-01758-0","article-title":"Mechanical dyssynchrony: How do we measure it, what it means, and what we can do about it","volume":"28","author":"Fudim M","year":"2021","unstructured":"Fudim M, Dalgaard F, Fathallah M, et al.. Mechanical dyssynchrony: How do we measure it, what it means, and what we can do about it. J Nucl Cardiol. 2021, 28:2174-84. 10.1007\/s12350-019-01758-0","journal-title":"J Nucl Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/jce.14180","article-title":"Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality","volume":"30","author":"Donnellan E","year":"2019","unstructured":"Donnellan E, Wazni OM, Saliba WI, et al.. Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality. J Cardiovasc Electrophysiol. 2019, 30:2427-32. 10.1111\/jce.14180","journal-title":"J Cardiovasc Electrophysiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1210356","article-title":"Biventricular pacing for atrioventricular block and systolic dysfunction","volume":"368","author":"Curtis AB","year":"2013","unstructured":"Curtis AB, Worley SJ, Adamson PB, et al.. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013, 368:1585-93. 10.1056\/NEJMoa1210356","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2021.07.010","article-title":"Electrophysiological manifestations of cardiac amyloidosis: JACC CardioOncology State-of-the-Art review","volume":"3","author":"Hartnett J","year":"2021","unstructured":"Hartnett J, Jaber W, Maurer M, et al.. Electrophysiological manifestations of cardiac amyloidosis: JACC CardioOncology State-of-the-Art review. JACC CardioOncol. 2021, 3:506-15. 10.1016\/j.jaccao.2021.07.010","journal-title":"JACC CardioOncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-21-0162","article-title":"JCS\/JHRS 2021 Guideline focused update on non-pharmacotherapy of cardiac arrhythmias","volume":"86","author":"Nogami A","year":"2022","unstructured":"Nogami A, Kurita T, Kusano K, et al.. JCS\/JHRS 2021 Guideline focused update on non-pharmacotherapy of cardiac arrhythmias. Circ J. 2022, 86:337-63. 10.1253\/circj.CJ-21-0162","journal-title":"Circ J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.63673","article-title":"Cardiac amyloidosis: a comprehensive review of pathophysiology, diagnostic approach, applications of artificial intelligence, and management strategies","volume":"16","author":"Ahammed MR","year":"2024","unstructured":"Ahammed MR, Ananya FN. Cardiac amyloidosis: a comprehensive review of pathophysiology, diagnostic approach, applications of artificial intelligence, and management strategies. Cureus. 2024, 16:e63673. 10.7759\/cureus.63673","journal-title":"Cureus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017335","article-title":"Cardiac resynchronization therapy for transthyretin cardiac amyloidosis","volume":"9","author":"Donnellan E","year":"2020","unstructured":"Donnellan E, Wazni OM, Hanna M, et al.. Cardiac resynchronization therapy for transthyretin cardiac amyloidosis. J Am Heart Assoc. 2020, 9:e017335. 10.1161\/JAHA.120.017335","journal-title":"J Am Heart Assoc"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.nuclcard.2005.06.088","article-title":"Onset of left ventricular mechanical contraction as determined by phase analysis of ECG-gated myocardial perfusion SPECT imaging: development of a diagnostic tool for assessment of cardiac mechanical dyssynchrony","volume":"12","author":"Chen J","year":"2005","unstructured":"Chen J, Garcia EV, Folks RD, et al.. Onset of left ventricular mechanical contraction as determined by phase analysis of ECG-gated myocardial perfusion SPECT imaging: development of a diagnostic tool for assessment of cardiac mechanical dyssynchrony. J Nucl Cardiol. 2005, 12:687-95. 10.1016\/j.nuclcard.2005.06.088","journal-title":"J Nucl Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-015-0333-y","article-title":"Comparison of phase dyssynchrony analysis using gated myocardial perfusion imaging with four software programs: Based on the Japanese Society of Nuclear Medicine working group normal database","volume":"24","author":"Nakajima K","year":"2017","unstructured":"Nakajima K, Okuda K, Matsuo S, et al.. Comparison of phase dyssynchrony analysis using gated myocardial perfusion imaging with four software programs: Based on the Japanese Society of Nuclear Medicine working group normal database. J Nucl Cardiol. 2017, 24:611-21. 10.1007\/s12350-015-0333-y","journal-title":"J Nucl Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/339579-a-challenging-case-of-wild-type-transthyretin-amyloidosis-attr-amyloidosis-treated-with-cardiac-resynchronization-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T06:24:09Z","timestamp":1751523849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/339579-a-challenging-case-of-wild-type-transthyretin-amyloidosis-attr-amyloidosis-treated-with-cardiac-resynchronization-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.87203","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,2]]}}}